RetinaCME
LECTURECME

Long-term Management of AMD: Examining New Evidence

Author(s)/Faculty: Judy E. Kim, MD; Nancy M. Holekamp, MD
Release Date: 10/24/2018Expiration Date: 10/23/2019
Credit Type: CMENumber of Credits: 0.75
Content Type: LectureProvider:
Age-related macular degeneration (AMD) is a leading cause of irreversible blindness and visual impairment. As prevalence of AMD continues to increase, it is estimated that nearly 3 million individuals in the United States will develop AMD by 2020. The integration of intravitreal anti-vascular endothelial growth factor (VEGF) therapies into therapeutic protocols has significantly improved the prognosis for patients with AMD. Unfortunately, initial vision gains are not always maintained; however, continued evaluation of anti-VEGF therapies and treatment protocols are now providing visual acuity gains with long-term therapy. In this educational activity, experts in the field will review intravitreal anti-VEGF treatment protocols, discuss outcomes from pinnacle clinical studies, and evaluate recent studies that demonstrate visual acuity gains with long-term anti-VEGF therapy.